Extend Study Population and Trial Design
DISORDERS, SYNDROME, IMMUNE SUPPRESSION
The study eligibility criteria were being a patient at the Immune Suppression Syndrome Clinic of the Mbarara Regional Referral Hospital, on anti-retroviral therapy for at least six months, and having an Alcohol Use Disorders Identification Test – Consumption, modified to represent the prior 3 months, score unhealthy drinking (≥ 3 for women or ≥ 4 (men), and having daily access to a working cell phone. 994 persons were screened, 321 were eligible and 270 were enrolled in the study [At baseline, the mean number of drinking days of the prior 21 was 9.4 (95% Confidence Interval [CI]: 9.1–9.8), mean PEth was 407.8 ng/mL (95% CI: 340.7-474.8), and 89.2% were virally suppressed [Participants in the SOC arm were invited to receive the intervention 9 months after baseline enrolment (wait list control). Those SOC arm participants accepting the intervention were allowed to choose to receive their boosters via live calls from the counselor, or automated calls via SMS or IVR.